Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05517837 · ClinicalTrials.gov registry record · Early Phase 1
A Phase 1, First-in-Human Study of BMS-986421 in Healthy Participants
A Early Phase 1 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 46
- Enrollment target
NCT05517837 is a Early Phase 1 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 46 participants.
The verdict
NCT05517837, a Early Phase 1 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability of BMS-986421 in healthy adult participants.
Interventions
- OTHER Placebo
- DRUG BMS-986421
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2022-09-13 |
| Est. Completion | 2023-07-14 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05517837
The ClinicalTrials.gov registry entry for NCT05517837 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05517837 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05517837 about?
NCT05517837 is a clinical study titled "A Phase 1, First-in-Human Study of BMS-986421 in Healthy Participants". The purpose of this study is to assess the safety and tolerability of BMS-986421 in healthy adult participants.
What is the current status of trial NCT05517837?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 46 participants. The study started on 2022-09-13. Estimated completion is 2023-07-14.
What interventions are being tested in trial NCT05517837?
The interventions under investigation include: Placebo (OTHER), BMS-986421 (DRUG).
Who is sponsoring clinical trial NCT05517837?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.